ABSTRACT
Background: A combination of methylprednisolone sodium succinate and tropisetron hydrochloride is commonly used to treat the nausea and vomiting associated with antineoplastic therapy. The objective of this study was to investigate the stability of tropisetron hydrochloride and methylprednisolone sodium succinate in 0.9% sodium chloride injection for up to 48 hours. Methods: Commercial solutions of methylprednisolone sodium succinate and tropisetron hydrochloride were obtained and further diluted with 0.9% sodium chloride injection to final concentrations of either 0.4 or 0.8 mg/mL (methylprednisolone sodium succinate) and 0.05 mg/mL (tropisetron). The admixtures were assessed for periods of up to 48 hours after storage at 4°C with protection from light and at 25°C without protection from light. Physical compatibility was determined visually, and the chemical compatibility was measured with high-performance liquid chromatography (HPLC) and by measurement of pH values. Results: HPLC analysis demonstrated that methylprednisolone sodium succinate and tropisetron hydrochloride in the various solutions were maintained at 97% of the initial concentrations or higher during the testing period. There were no changes observed by physical precipitation or pH in any of the prepared solutions. Conclusions: Tropisetron hydrochloride injection and methylprednisolone sodium succinate injection in 0.9% sodium chloride injection are stable for up to 48 hours at 4°C and 25°C.
Subject(s)
Anti-Inflammatory Agents/chemistry , Antiemetics/chemistry , Drug Incompatibility , Methylprednisolone Hemisuccinate/chemistry , Saline Solution/chemistry , Tropisetron/chemistry , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/analysis , Antiemetics/administration & dosage , Antiemetics/analysis , Chromatography, High Pressure Liquid/methods , Drug Stability , Humans , Injections , Methylprednisolone Hemisuccinate/administration & dosage , Methylprednisolone Hemisuccinate/analysis , Saline Solution/administration & dosage , Saline Solution/analysis , Tropisetron/administration & dosage , Tropisetron/analysisABSTRACT
BACKGROUND: About 50% of obsessive-compulsive disorder patients still suffer significant symptoms even after the recommended first-line therapy. This demonstrates the necessity to investigate strategies to improve alleviation of symptoms. OBJECTIVE: The main objective of this study was to investigate the efficacy of a 5-hydroxytryptophan 3 receptor antagonist, tropisetron, as an adjuvant therapy to selective serotonin reuptake inhibitors, in ameliorating obsessive-compulsive disorder symptoms. METHODS: Men and women between the ages of 18-60 years diagnosed with obsessive-compulsive disorder, based on DSM5, who had a Yale-Brown obsessive compulsive scale score of more than 21 were recruited in a double-blinded, parallel-group, placebo-controlled, clinical trial of 10 weeks to receive either tropisetron (5 mg twice daily) and fluvoxamine (100 mg daily initially followed by 200 mg daily after week 4) or placebo and fluvoxamine. The primary outcome of interest in this study was the Yale-Brown obsessive compulsive scale total score decrease from baseline. RESULTS: One hundred and eight participants were equally randomized into two groups; 48 participants in each group finished the trial. The Yale-Brown obsessive compulsive total score significantly dropped in both groups while the tropisetron group participants experienced a significantly higher decrease in their scores (Greenhouse-Geisser F(1.53-65.87)=3.516, p-value=0.04). No major adverse effect was observed in any of the groups. CONCLUSION: This trial showed a significant efficacy for tropisetron over placebo in treatment of obsessive-compulsive disorder symptoms when added to fluvoxamine.
Subject(s)
Fluvoxamine/administration & dosage , Obsessive-Compulsive Disorder/drug therapy , Selective Serotonin Reuptake Inhibitors/administration & dosage , Serotonin 5-HT3 Receptor Antagonists/administration & dosage , Tropisetron/administration & dosage , Adult , Double-Blind Method , Drug Therapy, Combination , Fluvoxamine/adverse effects , Humans , Male , Obsessive-Compulsive Disorder/physiopathology , Psychiatric Status Rating Scales , Serotonin 5-HT3 Receptor Antagonists/adverse effects , Selective Serotonin Reuptake Inhibitors/adverse effects , Tropisetron/adverse effectsABSTRACT
The transdermal route is a convenient non-invasive way for drug delivery, however, the hydrophobic compact nature of stratum corneum (SC) forms an obstacle hindering the diffusion of drugs particularly hydrophilic ones. Hence, the purpose of this study was to develop novel soft nano-vesicles, entitled Flexosomes, amalgamating two penetration enhancers, ethanol and one edge activator (EA) from various types and different hydrophilic-lipophilic balances. The tailored vesicles were loaded with tropisetron hydrochloride (TRO), a potent highly-soluble anti-emetic, and compared with ethosomes. Aiming to preclude the formation of rigid non-deformable mixed micelles, all critical parameters; EA type, phosphatidylcholine-to-EA molar ratio, and cholesterol concentration, were optimized proving their influences on vesicle-to-micelle transitions. The prepared formulations were characterized in terms of visual inspection, particle size, polydispersity, zeta potential, turbidity measurements, entrapment efficiency, and vesicle morphology. The permeation mechanisms were assessed by differential scanning calorimetry on isolated SC. The modified vesicles, based on ethanol and either vitamin E or PEGylated castor oil derivatives exhibited the highest transdermal fluxes confirmed by a deeply tracking to dermis using confocal laser microscopy. Both vesicles demonstrated higher bioavailability relative to ethosomes, topical and oral aqueous solutions. The findings endorsed the effectiveness of tailored nano-vesicles in boosting TRO skin transport suggesting their applicability with various drug entities for enhanced transdermal delivery.
Subject(s)
Antiemetics/administration & dosage , Drug Delivery Systems , Nanoparticles , Tropisetron/administration & dosage , Administration, Cutaneous , Animals , Antiemetics/pharmacokinetics , Biological Availability , Calorimetry, Differential Scanning , Chemistry, Pharmaceutical/methods , Ethanol/chemistry , Excipients/chemistry , Hydrophobic and Hydrophilic Interactions , Male , Micelles , Microscopy, Confocal , Particle Size , Rats , Skin/metabolism , Skin Absorption , Tropisetron/pharmacokineticsABSTRACT
Tropisetron is an adjuvant for dezocine used in intravenous patient-controlled analgesia (PCA) and has been reported to provide superior pain control. It is efficacious in reducing the institutional incidence of postoperative nausea and vomiting (PONV), which decreases resource utilization and cost. However, no scientific evidence has been reported in the literature demonstrating analytical confirmation of the compatibility and stability of the combination of dezocine and tropisetron. Thus, the present study aimed to investigate the stability of dezocine with tropisetron in 0.9% sodium chloride injection form for PCA administration.Commercial solutions of dezocine and tropisetron were combined and examined for compatibility and stability when diluted with 0.9% sodium chloride injection in polyolefin bags and glass bottles stored at 4°C or 25°C for up to 14 days. The initial concentrations were 40âmg/100âmL dezocine and 5âmg/100âmL tropisetron. For all samples, the compatibility parameters (including precipitation, cloudiness, discoloration, and pH values) were evaluated. Chemical stability was also determined using high-performance liquid chromatographic (HPLC) analysis.After a 14-day period of storage at 4°C or 25°C, the initial concentrations of dezocine and tropisetron were maintained at at least 98%. All of the mixtures remained clear and colorless throughout the observation period, and no color change or precipitation was observed.These results indicated that admixtures of 40âmg/100âmL dezocine and 5âmg/100âmL tropisetron in 0.9% sodium chloride injection were stable for at least 14 days when stored in polyolefin bags or glass bottles at 4°C or 25°C and protected from light.
Subject(s)
Analgesia, Patient-Controlled/methods , Bridged Bicyclo Compounds, Heterocyclic/therapeutic use , Tetrahydronaphthalenes/therapeutic use , Tropisetron/therapeutic use , Analgesics, Opioid/administration & dosage , Analgesics, Opioid/chemistry , Analgesics, Opioid/therapeutic use , Bridged Bicyclo Compounds, Heterocyclic/administration & dosage , Bridged Bicyclo Compounds, Heterocyclic/chemistry , Chromatography, Liquid/methods , Drug Combinations , Drug Stability , Humans , Injections/methods , Pharmacopoeias as Topic , Postoperative Nausea and Vomiting/drug therapy , Postoperative Nausea and Vomiting/prevention & control , Serotonin 5-HT3 Receptor Antagonists/administration & dosage , Serotonin 5-HT3 Receptor Antagonists/chemistry , Serotonin 5-HT3 Receptor Antagonists/therapeutic use , Sodium Chloride , Tetrahydronaphthalenes/administration & dosage , Tetrahydronaphthalenes/chemistry , Tropisetron/administration & dosage , Tropisetron/chemistryABSTRACT
While impairments of cognition in schizophrenia have the greatest impact on long-term functional outcome, the currently prescribed treatments, antipsychotic drugs (APDs), do not effectively improve cognition. Moreover, while more than 20â¯years have been devoted to the development of new drugs to treat cognitive deficits in schizophrenia, none have been approved to date. One area that has not been given proper attention at the preclinical or clinical stage of drug development is the chronic medication history of the test subject. Hence, very little is known about how chronic treatment with drugs that affect multiple receptors like APDs influence the response to a potential pro-cognitive agent. Therefore, the purpose of this study was to evaluate the α7 nicotinic acetylcholine receptor (α7 nAChR) partial agonist, tropisetron in rats chronically treated with APDs with distinct pharmacological profiles. Rats were treated orally with either risperidone (2.5â¯mg/kg/day) or quetiapine (25.0â¯mg/kg/day) for 30 or 90â¯days and then an acute injection of vehicle or tropisetron (3.0â¯mg/kg) was administered before training in a novel object recognition (NOR) task. After a 48 h delay (when recollection of the familiar object was impaired in vehicle-treated animals) neither 30 nor 90â¯days of risperidone or quetiapine treatment improved NOR performance. In contrast, tropisetron markedly improved NOR performance in rats treated with either APD for 30 or 90â¯days. These animal data reinforce the argument that two commonly prescribed APDs are not pro-cognitive agents and that α7 nAChR ligands like tropisetron have potential as adjunctive treatments in schizophrenia.